Johnson & Johnson Exits LAA Closure Market, Selling Heart Tech to New Startup
cardiovascularbusiness.com reports that Johnson & Johnson appears to be exiting the LAA (Left Atrial Appendage) closure market, selling its heart technology to a new startup.